Anteris Technologies Global Corp. — Interim / Quarterly Report 2015

Apr 29, 2015

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

30th April 2015

Company Announcements Office Australian Stock Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

Dear Sir/Madam,

Re: Appendix 4C - Quarterly Report

Please refer to the attached ‘Appendix 4C’ for details for the period ending 31st March 2015 for the Admedus Group.

• Revenue for the quarter up 47%

• Closing cash balance of $15.3M plus fully subscribed Rights Issue

• 15 US centres added during the quarter

Admedus had another productive quarter with revenue of $2.5M (with reported receipts of $1.9M) up 47% from the corresponding period of the previous year. The Company had a closing cash balance of $15.3M.

The Company continued to make strong progress in the launch of CardioCel[®] . The Company added 15 new centres in the US alone, increasing the number of centres in the US and Europe to 60. There are now more than 1600 patients implanted successfully with CardioCel to repair their heart defects. In addition, the Company also achieved initial sales for CardioCel in Hong Kong during the period as part of its continued global launch of the product.

Admedus continues to work with Professor Ian Frazer and his team to progress its therapeutic vaccines portfolio. The Herpes Simplex 2 (HSV-2) Phase II study is underway and actively recruiting study participants. The Company anticipates that recruitment of the Phase II HSV-2 study should be completed by the end of the quarter with interim results due to be delivered by the end of the 2015 calendar year.

During the quarter the Company also announced a capital raising, completing an oversubscribed placement for $12M and more recently completing a fully subscribed Rights Issue which raised a combined total of $28M.

Admedus also delivered a number of investor presentations during the quarter including presentations in New York at the BIO CEO and investor Forum, the Leerink Healthcare conference and the ASX Spotlight series.

Yours sincerely

==> picture [161 x 65] intentionally omitted <==

==> picture [595 x 44] intentionally omitted <==

Stephen Mann

Company Secretary

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity
Admedus Limited
ABN 35 088 221 078	Quarter ended (“current quarter”)
35 088 221 078	31 March 2015

Consolidated statement of cash flows

	Cash flows related to operating activities 1.1 Receipts from customers 1.2 Payments for (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital 1.3 Dividends received 1.4 Interest and other items of a similar nature received 1.5 Interest and other costs of finance paid 1.6 Income taxes refunded 1.7 Other – Commercialisation Australia Grant 1.8 Other – WA Innovation Voucher Program Grant Net operating cash flows	Current quarter $A’000	Year to date (9 months) $A’000
		1,941 (3,331) (157) (1,023) - (3,713) - - - (2) 148 -	6,534 (9,369) (410) (2,133) - (10,505) - 58 - (21) 148 -
		(6,137)	(15,698)

	Current quarter $A’000	Year to date (9 months) $A’000
1.8 Net operating cash flows (carried forward)	(6,137)	(15,698)
Cash flows related to investing activities 1.9 Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.10 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Other Net investing cash flows 1.14 Total operating and investing cash flows	- - (17) (40) - - - - - - - - -	- - (60) (338) - - - - - - - - (165)
	(57)	(563)
	(6,194)	(16,261)
Cash flows related to financing activities 1.15 Proceeds from issues of shares, options, etc. 1.16 Proceeds from sale of forfeited shares 1.17 Proceeds from borrowings 1.18 Repayment of borrowings 1.19 Dividends paid 1.20 Other / Transactions with Non-controlling interests Net financing cash flows	11,967 - - - -	12,053 - - - -
	11,967	12,053
Net increase (decrease) in cash held 1.21 Cash at beginning of quarter/year to date 1.22 Exchange rate adjustments to item 1.20 1.23 Cash at end of quarter	5,773 9,602 -	(4,208) 19,583 -
	15,375	15,375

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

1.24 Aggregate amount of payments to the parties included in item 1.2 1.25 Aggregate amount of loans to the parties included in item 1.11	Current quarter $A'000
	171
	-

• 1.26 Explanation necessary for an understanding of the transactions Consultancy services $66k Directors fees $105k

Non-cash financing and investing activities

• 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

• 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

3.1 Loan facilities 3.2 Credit standby arrangements	Amount available $A’000	Amount used $A’000
	-	-
	-	-

The Group holds an overdraft facility of $500,000 which is completely unused at the end of the current quarter. .

Reconciliation of cash

Reconciliation of cash
Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter $A’000	Previous quarter $A’000
4.1 Cash on hand and at bank 4.2 Deposits at call 4.3 Bank overdraft 4.4 Other (provide details)	15,375	9,602
	-	-
	-	-
	-	-
Total: cash at end of quarter(item 1.23)	15,375	9,602

Acquisitions and disposals of business entities

5.1 Name of entity 5.2 Place of incorporation or registration 5.3 Consideration for acquisition or disposal 5.4 Total net assets 5.5 Nature of business	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))

Compliance statement

• 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

• 2 This statement does ~~/does not*~~ (delete one) give a true and fair view of the matters disclosed.

Sign here: ....... . ... ................................................. Date: 30 April 2015 (Company Secretary)

Print name: Stephen Mann

Notes

1. The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.

3. Accounting Standards. ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.